JP2018518152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518152A5 JP2018518152A5 JP2017550493A JP2017550493A JP2018518152A5 JP 2018518152 A5 JP2018518152 A5 JP 2018518152A5 JP 2017550493 A JP2017550493 A JP 2017550493A JP 2017550493 A JP2017550493 A JP 2017550493A JP 2018518152 A5 JP2018518152 A5 JP 2018518152A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- equivalent
- lhr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 37
- 102000023108 LH Receptors Human genes 0.000 claims description 31
- 108010011942 LH Receptors Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 150000007523 nucleic acids Chemical group 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108091035707 Consensus sequence Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 108091008039 hormone receptors Proteins 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229940040129 luteinizing hormone Drugs 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139623P | 2015-03-27 | 2015-03-27 | |
| US62/139,623 | 2015-03-27 | ||
| PCT/US2016/024354 WO2016160618A2 (en) | 2015-03-27 | 2016-03-25 | Car t-cell therapy directed to lhr for the treatment of solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018518152A JP2018518152A (ja) | 2018-07-12 |
| JP2018518152A5 true JP2018518152A5 (enExample) | 2019-05-09 |
Family
ID=57007252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550493A Pending JP2018518152A (ja) | 2015-03-27 | 2016-03-25 | 充実性腫瘍を処置するためのｌｈｒに指向されたｃａｒ ｔ細胞治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11136401B2 (enExample) |
| EP (1) | EP3273994B1 (enExample) |
| JP (1) | JP2018518152A (enExample) |
| CN (1) | CN107530427A (enExample) |
| AU (1) | AU2016243124A1 (enExample) |
| CA (1) | CA2981142A1 (enExample) |
| ES (1) | ES2904573T3 (enExample) |
| IL (1) | IL254701A0 (enExample) |
| WO (1) | WO2016160618A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016243124A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cell therapy directed to LHR for the treatment of solid tumors |
| AU2016270474A1 (en) | 2015-06-04 | 2018-01-04 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
| JP6896057B2 (ja) | 2016-07-12 | 2021-06-30 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | 抗原結合分子及びその使用方法 |
| JP2020501512A (ja) * | 2016-09-23 | 2020-01-23 | ユニバーシティ オブ サザン カリフォルニア | キメラ抗原受容体およびその組成物ならびにそれらの使用の方法 |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| IL311608A (en) * | 2017-03-13 | 2024-05-01 | Poseida Therapeutics Inc | Preparations and methods for the selective elimination and replacement of hematopoietic stem cells |
| CN107354199A (zh) * | 2017-07-04 | 2017-11-17 | 武汉波睿达生物科技有限公司 | 一种检测靶向cd30的cart细胞中car表达的荧光定量试剂盒 |
| EP3684803A1 (en) | 2017-09-22 | 2020-07-29 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
| EP3675878A4 (en) | 2017-10-02 | 2021-06-16 | Fred Hutchinson Cancer Research Center | LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS |
| AU2019282620A1 (en) | 2018-06-04 | 2020-12-17 | Precigen, Inc. | MUC16 specific chimeric antigen receptors and uses thereof |
| CN112639102B (zh) * | 2018-08-29 | 2024-03-01 | 南京传奇生物科技有限公司 | 抗间皮素嵌合抗原受体(car)构建体及其用途 |
| EP3864414A4 (en) | 2018-10-13 | 2023-03-29 | Memorial Sloan-Kettering Cancer Center | METHODS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF SUBJECTS AT RISK OF A POOR RESPONSE TO CAR T CELL THERAPY |
| KR20210137427A (ko) * | 2019-01-06 | 2021-11-17 | 아빈투스 바이오, 인코포레이티드 | Car t 세포 방법 및 작제물 |
| CA3129501A1 (en) | 2019-02-15 | 2020-08-20 | University Of Southern California | Lym-1 and lym-2 antibody compositions and improved car constructs |
| WO2020247837A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| EP4087590A4 (en) * | 2020-01-12 | 2024-05-15 | Vanderbilt University | HUMAN ANTIBODIES AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS |
| JP2023532789A (ja) * | 2020-07-07 | 2023-07-31 | サーモソーム ゲゼルシャフト ミット べシュレンクテル ハフツング | リポソーム製剤 |
| US20230382978A1 (en) * | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN113156142B (zh) * | 2021-04-16 | 2024-09-27 | 苏州才博医学科技有限公司 | 一种针对异体cart细胞特异性抗体的检测方法 |
| WO2025117530A2 (en) * | 2023-11-27 | 2025-06-05 | The Trustees Of Columbia University In The City Of New York | Tmem106b(120-254) aggregate-binding antibody |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US707993A (en) | 1901-05-16 | 1902-08-26 | Clinton J Warren | Machine for corking bottles. |
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| EP1224465B1 (en) | 1999-09-27 | 2005-12-21 | Clifford L. Librach | Detection of hla-g |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ES2302726T3 (es) | 2000-02-24 | 2008-08-01 | Invitrogen Corporation | Estimulacion y concentracion simultanea de celulas. |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| JP4413495B2 (ja) | 2001-03-13 | 2010-02-10 | ノバルティス アクチエンゲゼルシャフト | レンチウィルスパッケージング構築物 |
| DK2301965T3 (en) | 2002-10-16 | 2015-04-27 | Purdue Pharma Lp | Antibodies that bind to cell-associated CA 125 / O722P and methods of use thereof |
| KR101024443B1 (ko) | 2003-01-07 | 2011-03-23 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질의 제조 방법 |
| AU2004219603A1 (en) | 2003-03-11 | 2004-09-23 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related disease |
| GB0408449D0 (en) | 2004-04-15 | 2004-05-19 | Banerjee Subhasis | Diagnostic and therapeutic applications of soluble lhcge protein |
| CA2577815A1 (en) | 2004-08-20 | 2006-03-30 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| CN1331887C (zh) | 2004-08-20 | 2007-08-15 | 上海美恩生物技术有限公司 | 抗hla－dr10的淋巴瘤特异性嵌合单抗 |
| EP2465872A3 (en) | 2004-10-25 | 2012-12-19 | Merck Sharp & Dohme Corporation | Anti-ADDL antibodies and uses thereof |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
| JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| US8680055B2 (en) * | 2009-06-03 | 2014-03-25 | University Of Southern California | Methods for decreasing steroidogenesis in prostate cancer cells |
| EP2462161B1 (en) | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3693017A1 (en) * | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| AU2013222288A1 (en) | 2012-02-22 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence |
| HK1203393A1 (en) | 2012-04-11 | 2015-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| AU2013329311A1 (en) | 2012-10-09 | 2015-04-30 | Igenica Biotherapeutics, Inc. | Anti-C16orf54 antibodies and methods of use thereof |
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US20140348744A1 (en) * | 2013-05-24 | 2014-11-27 | Jacek K. Pinski | Compositions and methods for regulating cancer-related signaling pathways |
| WO2015025825A1 (ja) | 2013-08-23 | 2015-02-26 | 学校法人藤田学園 | インフルエンザウイルスに対する抵抗力の判定方法 |
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
| AU2016243124A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cell therapy directed to LHR for the treatment of solid tumors |
| US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| EP3568469A4 (en) | 2017-02-21 | 2020-11-11 | Eutilex Co., Ltd. | COMPOSITIONS OF CAR-T CELLS DIRECTED AGAINST HLA-DR AND THEIR MANUFACTURING AND USE PROCEDURES |
-
2016
- 2016-03-25 AU AU2016243124A patent/AU2016243124A1/en not_active Abandoned
- 2016-03-25 WO PCT/US2016/024354 patent/WO2016160618A2/en not_active Ceased
- 2016-03-25 ES ES16773871T patent/ES2904573T3/es active Active
- 2016-03-25 EP EP16773871.5A patent/EP3273994B1/en not_active Not-in-force
- 2016-03-25 CA CA2981142A patent/CA2981142A1/en not_active Abandoned
- 2016-03-25 JP JP2017550493A patent/JP2018518152A/ja active Pending
- 2016-03-25 US US15/561,967 patent/US11136401B2/en active Active
- 2016-03-25 CN CN201680024480.2A patent/CN107530427A/zh active Pending
-
2017
- 2017-09-26 IL IL254701A patent/IL254701A0/en unknown
-
2021
- 2021-08-31 US US17/462,987 patent/US20210403585A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/669,185 patent/US20250129171A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518152A5 (enExample) | ||
| AU2023200608B2 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
| JP2018513687A5 (enExample) | ||
| JP2018511319A5 (enExample) | ||
| CN109843927B (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP5913547B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| JP2018524973A5 (enExample) | ||
| Inaguma et al. | Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H | |
| JP2009100745A5 (enExample) | ||
| EP3349792A1 (en) | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- | |
| JP7712338B2 (ja) | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ | |
| JP2018529380A5 (enExample) | ||
| JP2008535477A5 (enExample) | ||
| JP2020501512A5 (enExample) | ||
| CN119185533A (zh) | 新型免疫检查点抑制剂 | |
| CN116640216B (zh) | 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用 | |
| JP2021507877A5 (enExample) | ||
| JP2016514099A5 (enExample) | ||
| CN110637031B (zh) | 程序性死亡蛋白1(pd-1)的重组抗体及其用途 | |
| CN113412130A (zh) | 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向 | |
| JP2015501146A5 (enExample) | ||
| WO2005070965A2 (en) | Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases | |
| JP2018199675A5 (enExample) | ||
| AU2019267050B2 (en) | Epitope of regulatory T cell surface antigen and antibody specifically binding thereto | |
| Hayes et al. | ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1) |